\begin{tabular*}{\textwidth}{@{\extracolsep\fill}clllllllllll@{\extracolsep\fill}}
\toprule
&  & \multicolumn{3}{c}{Final Selection (\%)$^1$} & \multicolumn{3}{c}{Allocations (\%)} & &  &  &  \\
\multirow{2}{2em}{Alpha} & \multirow{2}{2em}{Method} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{MTD} & \multirow{2}{2em}{Above MTD} & \multirow{2}{2em}{Below MTD} & \multirow{2}{2em}{Toxic~\%$^2$} & \multirow{2}{2em}{DLTs} & \multirow{2}{2em}{Trial Size} & \multirow{2}{2em}{Days}  \\ \\ 
\midrule
\multirow{4}{2em}{0} & CRM & 51 & 23 & 26 & 32 & 30 & 38 & 30 & 7.8 & 27.8 & 1522\\
 & AIDE-CRM & 51 & 23 & 26 & 32 & 30 & 38 & 30 & 7.8 & 23.9 & 1307\\
 & $\alpha$-CRM & 52 & 27 & 21 & 32 & 33 & 35 & 33 & 8.1 & 23.9 & 1306\\
 & IPDE-POCRM & 52 & 29 & 20 & 32 & 35 & 33 & 35 & 8.2 & 23.5 & 1279\\
\midrule
\multirow{4}{2em}{0.3} & CRM & 51 & 23 & 26 & 32 & 30 & 38 & 30 & 7.8 & 27.8 & 1522\\
 & AIDE-CRM & 50 & 19 & 31 & 31 & 28 & 40 & 33 & 7.9 & 23.9 & 1300\\
 & $\alpha$-CRM & 52 & 24 & 24 & 32 & 31 & 37 & 36 & 8.2 & 23.8 & 1298\\
 & IPDE-POCRM & 52 & 25 & 23 & 33 & 32 & 35 & 37 & 8.4 & 23.5 & 1278\\
\midrule
\multirow{4}{2em}{0.6} & CRM & 52 & 22 & 26 & 32 & 30 & 38 & 30 & 7.8 & 27.7 & 1518\\
 & AIDE-CRM & 49 & 16 & 35 & 31 & 26 & 43 & 32 & 8.0 & 23.9 & 1302\\
 & $\alpha$-CRM & 51 & 21 & 27 & 32 & 30 & 38 & 35 & 8.3 & 23.8 & 1295\\
 & IPDE-POCRM & 52 & 22 & 26 & 32 & 31 & 37 & 37 & 8.5 & 23.4 & 1271\\
\midrule
\multirow{4}{2em}{0.9} & CRM & 51 & 23 & 26 & 32 & 30 & 38 & 30 & 7.8 & 27.7 & 1516\\
 & AIDE-CRM & 46 & 14 & 40 & 30 & 25 & 46 & 33 & 8.0 & 23.8 & 1297\\
 & $\alpha$-CRM & 50 & 19 & 31 & 32 & 28 & 41 & 36 & 8.5 & 23.7 & 1291\\
 & IPDE-POCRM & 51 & 18 & 31 & 32 & 29 & 40 & 37 & 8.7 & 23.2 & 1264\\
\bottomrule
\end{tabular*}
